Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jun 2, 2023
Discovery & Translation

Single-cell T cell atlas identifies new subsets; plus CoRegen’s cell therapy and more

BioCentury’s roundup of translational news
BioCentury | Oct 11, 2018
Financial News

Cancer company Rgenix raises $40M series C

BioCentury | Nov 3, 2017
Product Development

Liver X factor

How Rgenix’s liver X agonist could help overcome checkpoint resistance in cancer
BioCentury | Jan 12, 2017
Clinical News

RGX-104: Ph I started

BioCentury | Jan 11, 2017
Clinical News

Allergan discloses Phase II miss in LXR program

BioCentury | Nov 11, 2016
Clinical News

VTP-38543: Ph I/II data

BioCentury | Sep 19, 2016
Company News

Vitae, Allergan deal

BioCentury | Sep 14, 2016
Top Story

Allergan acquiring Vitae

BioCentury | Jun 16, 2016
Financial News

Cancer play Rgenix raises $33M

Items per page:
1 - 10 of 11
Help Center
Username
Request a Demo
Request Training
Ask a Question